Investor Relations

Latest Financial Results

Q3 2022

Quarter Ended Sep 30, 2022

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

Kiora is a clinical-stage biotechnology company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with other DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing..

Stock Information

IR Contacts

Company

Kiora Pharmaceuticals, Inc.
1371 East 2100 South
Suite 200
Salt Lake City, UT 84105

Investor Relations

Francina Agosti, PhD
T: 617-546-0742
fagosti@reportablenews.com

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.